Navigation Links
Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
Date:12/7/2007

Celldex also receives approval from Health Canada to open clinical sites

and establishes a collaboration with the National Cancer Institute

PHILLIPSBURG, N.J., Dec. 7 /PRNewswire/ -- Celldex Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Celldex's CDX-110 for the treatment of EGFRvIII expressing Glioblastoma Multiforme (GBM). GBM is the most common and aggressive form of brain cancer. CDX-110 is an immunotherapy that targets the tumor-specific growth promoter EGFRvIII. Celldex Therapeutics announced a definitive merger agreement with AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) in October 2007.

In the ACTIVATE phase IIa study, CDX-110 treated GBM patients showed a median survival time of 30 months, more than a 100 percent increase in survival, versus the historical control's median of 14.5 months. The study has demonstrated a median time-to-progression of 13 months (p=0.0001) versus the historical control's median of 6.4 months. An extension study, ACT II, which combines CDX-110 with chemotherapy in a similar patient population, has not yet reached median time-to-progression or survival. However, preliminary progression free survival (PFS) and overall survival (OS) data in ACT II look very similar to the ACTIVATE experience, and the data suggest that chemotherapy and CDX-110 can be administered concurrently while still maintaining strong immune responses.

In September, Celldex randomized its first patient into ACT III, a definitive Phase II/III randomized study of CDX-110 with radiation and temozolomide in patients with newly-diagnosed GBM. The clinical trial is investigating the anticancer activity, impact on survival, a
'/>"/>

SOURCE Celldex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015 Semler Scientific, Inc. (Nasdaq: ... that develops, manufactures and markets products that assist healthcare ... reported financial results for the first quarter ended March ... of 2015, Semler reported continued progress with year over ... revenue growth of 14%," said Doug Murphy-Chutorian , ...
(Date:5/1/2015)...  Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ... the results of the Phase 3 Rocket 1 trail ... failing to meet its end points, compelling data from ... future studies. An analyst report on AERI ... review, analyst summary, valuation, and recommendation can be viewed ...
(Date:4/30/2015)... 30, 2015  Accuray Incorporated (Nasdaq: ARAY ... agreement with MIM Software Inc. to further develop ... and CyberKnife ® product portfolios. The new software ... This is Accuray,s second collaboration with MIM; the ... first iPad-based treatment plan review capability, PlanTouch™. ...
Breaking Medicine Technology:Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3
(Date:5/3/2015)... NuevaCare announced today that it will ... seminars. The first event will take place on Wednesday, ... to be held at The Magnolia of Millbrae. The ... during the Dementia Conference to be held at the ... an excellent opportunity to learn about the MnemeTherapy® approach ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... event today, Saturday, May 2nd at the MGM Grand Garden ... able to secure tickets for both the actual fight and ... have wanted for more than five years was finally been ... step inside the ring to fight Manny “Pac-Man” Pacquiao in ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 We are ... The Delray Recovery Center as one of the Top ... known in the addiction treatment field for their ethics ... to innovate and to continue their educational efforts. The ... workplace environment, never forgetting their purpose – to help ...
(Date:5/2/2015)... ZoomCare, the Portland-based innovator of on-demand ... offer its new healthcare insurance to individuals and small ... Insurance System is the nation’s first health insurance system ... ZOOM+ Personal Health Insurance was ZoomCare’s first such filing ... subject to review and regulation by the Oregon Insurance ...
(Date:5/1/2015)... Jusuru International has been awarded the prestigious ... its flagship nutritional supplement, Liquid BioCell™ Life, and the ... new logo, new packaging, new products, and new messaging. ... identify and promote programs that serve as examples of ... Jusuru International for their outstanding accomplishments and contributions to ...
Breaking Medicine News(10 mins):Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5
... , , , , , , ... Medical,International Limited (NYSE: MR ), a leading developer, ... at its annual general meeting of shareholders held in Hong ... the meeting, Mindray Medical International,s shareholders approved the,re-election of directors ...
... causes more pain than vodka, study finds , FRIDAY, Dec. ... a common indulgence -- and nasty hangovers a common consequence. ... lighter-colored beverages, they might feel a little better the next ... contain more toxic properties that provoke more painful hangovers than ...
... , , , NEWPORT BEACH, Calif., Dec. 18 ... announced today that it has given notice that it is ... Cumulative Convertible Preferred Stock ("Series B Preferred Stock") (NHP-PB - ... price per share of $103.875 plus an amount equal to ...
... thoughts may help explain interpersonal problems , FRIDAY, Dec. ... are less active than expected when they,re engaged in ... difficulties, say British researchers. , Using functional MRI, they ... whom had autism, while they were asked questions about ...
... CentraCare president is new chair , ST. PAUL, Minn., Dec. ... systems, recently elected or re-elected the following members to its board for ... Chair - Terence Pladson, M.D., president, CentraCare Health System, ... CEO, Queen of Peace Hospital, New Prague, Secretary/treasurer - ...
... , , HOUSTON, Dec. 18 ... largest provider of deathcare products and services in North America, ... has extended the expiry time of its offer (the "Offer") ... and outstanding common shares in the capital of Keystone North ...
Cached Medicine News:Health News:Mindray Medical International Limited Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting 2Health News:For a Lighter Hangover, Avoid Darker Drinks 2Health News:For a Lighter Hangover, Avoid Darker Drinks 3Health News:For a Lighter Hangover, Avoid Darker Drinks 4Health News:Nationwide Health Properties, Inc. Announces the Redemption of All Outstanding Shares of 7.75% Series B Cumulative Convertible Preferred Stock 2Health News:Brain Imaging Sheds Light on Social Woes Related to Autism 2Health News:Minnesota Hospital Association Elects, Re-Elects Members to Board 2Health News:Service Corporation International Extends Offer for Keystone North America Inc. 2Health News:Service Corporation International Extends Offer for Keystone North America Inc. 3
... low profile implantable bipolar fixed screw-in ... either the atrium or the ventricle. ... a screwdriver shape stylet which is ... ring tip and fixation screw are ...
... are implantable bipolar extendable/retractable screw-in permanent ... the atrium or the ventricle. The ... extended or retracted by turning the ... an anti-chattering mechanism for steady pacing ...
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics....
Used to occupy an empty hole which is not being used in an implantablepacemaker header....
Medicine Products: